Tweet NASHVILLE, TN, Gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital.

To export Objective GI funding data to PDF and Excel, clickClick here for more funding data on Objective GITo export Objective GI funding data to PDF and Excel, click here Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States.

"This investment marks a major step forward for our company to leverage our research platform and strengthen our core offerings," said Colleen Hoke, CEO of Objective GI.

This latest key investment in Objective GI comes from TKS 1, a venture capital collaboration between SPRIM and Tikehau Capital (TKO.FP), an alternative asset management and investment company.

"We're excited to offer the funding and look forward to accelerated growth to the Objective GI infrastructure and network." | To read full story, visit https://startuparound.com/read/1577197814.9893327/Objective-GI-Receives-Investment?ref=audio_experience